Skip to content

Study · Not a test of the peptide alone · 2026

3 results

Sprayable bioadhesive microcarriers loaded with Tβ4-Engineered ADSC exosomes for diabetic wound healing.

Ding Y, Huang D, Zhao Z, Feng H, Zhou S, Qian D, Zhang Y, Zhao Y, Zhou M

Bioactive materials23 Jun 2026

PMID42383202 (opens in a new tab)PMCIDPMC13316191 (opens in a new tab)DOI10.1016/j.bioactmat.2026.06.024 (opens in a new tab)PepBankPUB-42383202
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 01AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Efficacy outcome

    In diabetic wound models, a sprayable microcarrier loaded with Tβ4-overexpressing stem cell exosomes accelerated wound repair.

    In plain wordsIn diabetic wound models, a spray with exosomes from Tβ4-engineered stem cells sped up wound repair.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseDiabetic wound repair
    Study

    n: not reported in source

    Outcome group
    Wound healing · Skin and wound

    Source sentences

    Summary
    accelerate wound repair in diabetic models
    1 context sentence
    Summary · context
    Here, we report a novel microcarrier platform loaded with thymosin β4 (Tβ4)-overexpressing stem cell-derived exosomes for a sprayable diabetic wound dressing.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  2. 02LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism

    A microcarrier loaded with Tβ4-overexpressing stem cell exosomes significantly enhanced macrophage efferocytosis.

    In plain wordsIn lab tests, a carrier with exosomes from Tβ4-engineered stem cells increased macrophage clearance of dying cells.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseMacrophage efferocytosis
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    significantly enhance macrophage efferocytosis
    1 context sentence
    Summary · context
    Here, we report a novel microcarrier platform loaded with thymosin β4 (Tβ4)-overexpressing stem cell-derived exosomes for a sprayable diabetic wound dressing.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  3. 03LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism

    A microcarrier loaded with Tβ4-overexpressing stem cell exosomes suppressed inflammatory signaling.

    In plain wordsIn lab tests, a carrier with exosomes from Tβ4-engineered stem cells reduced inflammatory signaling.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseInflammatory signaling
    Study

    n: not reported in source

    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    suppress inflammatory signaling
    1 context sentence
    Summary · context
    Here, we report a novel microcarrier platform loaded with thymosin β4 (Tβ4)-overexpressing stem cell-derived exosomes for a sprayable diabetic wound dressing.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.